Hereditary Cryopyrin-Associated Periodic Syndromes (Cryopyrinopathies)

ByGil Amarilyo, MD, Tel Aviv University
Reviewed/Revised Dec 2023
View Patient Education

The hereditary cryopyrin-associated periodic syndromes are a group of autosomal dominant autoinflammatory conditions characterized by recurrent episodes of fever and inflammatory symptoms; they include familial cold autoinflammatory syndrome, Muckle-Wells syndrome, and neonatal-onset multisystem autoinflammatory disease. Diagnosis is clinical. Treatment is with interleukin-1 inhibitors.

Hereditary cryopyrin-associated periodic syndromes (CAPS) represent a spectrum of clinically overlapping autoinflammatory diseases.

They are due to

  • Mutations in the NLRP3 gene encoding the protein cryopyrin, which mediates inflammation and interleukin-1 beta (IL-1 beta) processing

Cryopyrin activity is augmented, triggering increased release of IL-1 beta from the NLRP3 inflammasome; the result is inflammation and fever.

Familial cold autoinflammatory syndrome (FCAS) typically causes a cold-induced urticarial rash accompanied by fever, conjunctivitis, and sometimes arthralgias. The condition often appears in the first year of life.

Muckle-Wells syndrome (MWS) causes intermittent fevers, urticarial rash, joint pain, and progressive sensorineural hearing loss; 25% of patients develop renal amyloidosis.

Neonatal-onset multisystem autoinflammatory disease (NOMID) tends to cause joint and limb deformities, facial deformities, chronic aseptic meningitis, cerebral atrophy, uveitis, papillary edema, delayed development, and amyloidosis, in addition to fever and a migratory urticarial rash. As many as 20% of patients die by age 20 if untreated.

Autoinflammatory Periodic Fever Disorders

CAPS = cryopyrin-associated periodic syndromes; FMF = familial Mediterranean fever; NOMID = neonatal-onset multisystem inflammatory disease; PFAPA = periodic fevers with aphthous stomatitis, pharyngitis, and adenitis; TRAPS = tumor necrosis factor receptor–associated periodic syndrome.

Adapted from Sag E, Bilginer Y, Ozen S: Autoinflammatory diseases with periodic fevers. Curr Rheumatol Rep 19(7):41, 2017. doi: 10.1007/s11926-017-0670-8

Diagnosis of Hereditary CAPS

  • Clinical criteria

Proposed diagnostic criteria for CAPS include increased markers of inflammation and at least 2 of the following (1) :

  • Urticaria-like rash

  • Episodes triggered by cold and/or stress

  • Sensorineural hearing loss

  • Musculoskeletal symptoms, including arthralgias, arthritis, and myalgias

  • Chronic aseptic meningitis

  • Skeletal abnormalities, including epiphyseal overgrowth and frontal bossing

These criteria have a sensitivity of 81% and specificity of 94% (1). The European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology (ACR) also have outlined diagnostic considerations for CAPS (2).

Although early age of onset makes the diagnosis of CAPS more likely, CAPS should also be considered in people with a late age of onset because of the disease's rarity (such that it is often not considered), mild phenotypes (which can escape recognition in early life), and somatic mutations (no family history) (3).

Diagnosis references

  1. 1. Kuemmerle-Deschner JB, Ozen S, Tyrrell PN, et al: Diagnostic criteria for cryopyrin-associated periodic syndrome (CAPS). Ann Rheum Dis 76(6):942-947, 2017. doi: 10.1136/annrheumdis-2016-209686

  2. 2. Romano M, Arici ZS, Piskin D, et al: The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist. Ann Rheum Dis 81(7):907-921, 2022. doi: 10.1136/annrheumdis-2021-221801

  3. 3. Welzel T, Kuemmerle-Deschner JB: Diagnosis and management of the cryopyrin-associated periodic syndromes (CAPS): What do we know today? J Clin Med 10(1):128, 2021. doi: 10.3390/jcm10010128

Treatment of Hereditary CAPS

  • IL-1 inhibitors

1, 2, 3).

Treatment references

  1. 1. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al: Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 360(23):2416–2425, 2009. doi: 10.1056/NEJMoa0810787

  2. 2. Sibley CH, Plass N, Snow J, et al: Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: A cohort study to determine three- and five-year outcomes. Arthritis Rheum 64(7):2375–2386, 2012. doi: 10.1002/art.34409

  3. 3. Hoffman HM, Throne ML, Amar NJ, et al: Long-term efficacy and safety profile of rilonacept in the treatment of cryopyrin-associated periodic syndromes: Results of a 72-week open-label extension study. Clin Ther 34(10):2091–2103, 2012. doi: 10.1016/j.clinthera.2012.09.009

Drugs Mentioned In This Article

quizzes_lightbulb_red
Test your KnowledgeTake a Quiz!
Download the free Merck Manual App iOS ANDROID
Download the free Merck Manual App iOS ANDROID
Download the free Merck Manual App iOS ANDROID